A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorEli Lilly and Company
About this trial
The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase.
Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.
Eligibility criteria
Qualifiers
30 kilogram per square meter (kg/m2) OR
high blood pressure
dyslipidemia
obstructive sleep apnea, or
Disqualifiers
Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
Have type 1 diabetes or type 2 diabetes
heart attack
Trial design
Treatments tested in this trial
- Eloralintide
- Placebo
Treatment groups
1,980 Participants
are divided into 5 treatment groupsLocations
169Argentina
CARDIAMET Investigaciones MédicasC1014ACP, Buenos Aires Argentina
Cardiología Palermo1425, Buenos Aires Argentina
Centro Médico ViamonteC1120AAC, Buenos Aires Argentina
Cicemo Srl1424, Buenos Aires Argentina
Sponsors and collaborators
Eli Lilly and Company
Lead sponsor
Source ClinicalTrials.gov